Market closed
Processa Pharmaceuticals Inc./$PCSA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
Ticker
$PCSA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
10
PCSA Metrics
BasicAdvanced
$1.4M
-
-$3.87
0.75
-
Price and volume
Market cap
$1.4M
Beta
0.75
52-week high
$0.56
52-week low
$0.21
Average daily volume
3.6M
Financial strength
Current ratio
1.222
Quick ratio
0.777
Long term debt to equity
0.029
Total debt to equity
4.334
Management effectiveness
Return on assets (TTM)
-167.08%
Return on equity (TTM)
-354.51%
Valuation
Price to book
0.56
Price to tangible book (TTM)
0.56
Price to free cash flow (TTM)
-0.07
Growth
Earnings per share change (TTM)
-54.33%
3-year earnings per share growth (CAGR)
-36.21%
PCSA News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Processa Pharmaceuticals Inc. stock?
Processa Pharmaceuticals Inc. (PCSA) has a market cap of $1.4M as of April 16, 2025.
What is the P/E ratio for Processa Pharmaceuticals Inc. stock?
The price to earnings (P/E) ratio for Processa Pharmaceuticals Inc. (PCSA) stock is 0 as of April 16, 2025.
Does Processa Pharmaceuticals Inc. stock pay dividends?
No, Processa Pharmaceuticals Inc. (PCSA) stock does not pay dividends to its shareholders as of April 16, 2025.
When is the next Processa Pharmaceuticals Inc. dividend payment date?
Processa Pharmaceuticals Inc. (PCSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Processa Pharmaceuticals Inc.?
Processa Pharmaceuticals Inc. (PCSA) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.